Drug intelligence / Profile preview

GLR1075

Development stage: Phase 1
Lead developer: Gan & Lee Pharmaceuticals
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

GLR1075 is a recombinant human albumin formulation being developed by Gan & Lee Pharmaceuticals for the treatment of hypoalbuminemia in patients with liver cirrhosis and ascites. As a humanized recombinant protein drug, its active ingredient, recombinant human albumin, shares the same amino acid sequence and a similar three-dimensional structure as natural human serum albumin. This allows it to perform the core physiological functions of albumin, such as correcting colloid osmotic pressure imbalances and improving pathological microenvironments, while potentially reducing the supply pressure and safety risks associated with blood-derived albumin products. GLR1075 is currently being evaluated in Phase 1 clinical trials.

Other names: recombinant human albuminrecombinant human albumin injection重组人白蛋白重组人白蛋白注射液

Beyond the preview

Go deeper on GLR1075.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLR1075.